Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Ratings reports ...

CAMBRIDGE, MA—Mersana Therapeutics, Inc. (NASDAQ:MRSN) recently reported that Ashish Mandelia, the company's Vice President ...

Mersana Therapeutics Inc (MRSN) stock saw a decline, ending the day at $0.53 which represents a decrease of $-0.02 or -3.64% from the prior close of $0.55. The stock opened at $0.54 and touched a low ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report) ...

At the close in NYSE, the Dow... H.C. Wainwright analyst Edward White maintained a Buy rating on Mersana Therapeutics (NASDAQ:MRSN) Inc on Friday, setting a price target of $28, which is ...

In recent transactions disclosed by Mersana Therapeutics, Inc. (NASDAQ:MRSN), Timothy B. Lowinger, the company's Senior Vice ...

Wedbush reiterated their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report released on Friday morning,RTT News reports. They currently have a $4.00 ...

Mersana Therapeutics Inc (MRSN) stock saw a decline, ending the day at $0.61 which represents a decrease of $-0.03 or -4.69% from the prior close of $0.64. The stock opened at $0.65 and touched a low ...

Robert W. Baird analyst Michael Ulz reiterated a Buy rating on Mersana Therapeutics (NASDAQ:MRSN) Inc on Friday, setting a price target of $30, which is approximately 51.67% above... Investing.com ...

On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of ...